Good afternoon EVEsters..as the price is heading upwards and in particular for many of the newbies who have joined to understand why the surge please check news reports that have been added over past few days and the timeline this morning.
I thought it owuld also be good to add the previous milestones to see where the company has been and why it should be a solid performer , IMO, going into 2018. These re ANN's out from the ASX for the past 2 years.
2016
*
FEB 2016 OMNI Glucocontrol Manufacturing bgegins
*
MAY 2016 OMNI Glucocontrol Pre-Meal drink launched
*
JULY 2016 OMNI Glucocontrol continues momentum
Highlights
1) A significant second manufacturing order has been received for GlucoControlTM, corresponding with commencement of increased consumer marketing
2)Marketing programs ramping up with product availability
3) ‘Diet for Diabetes’ educational seminars being held across Australia
4) Significant progress on distribution agreements for US, UK and China EVE Investments (ASX:EVE),
A second large manufacturing order for GlucoControlTM has been received to provide additional volume of stock for distribution into selected pharmacies. This second production will increase the availability of GlucoControlTM in pharmacy outlets across Australia and will coincide with marketing programs designed to build product and brand awareness.
*
AUG 2016 OMNIBLEND Innovation enters into US Representation Deal
*
SEP 2016 OMNI Glucocontrol receives good Bio outcomes on improving Long Term Glycaemic Control.
*
NOV 2016 TRT GROUP CHINA INVESTS in EVE INVESTMENTS.
Tianjin Tongrentang Group Tianjin Tongrentang Group is one of China’s oldest pharmaceutical and traditional chinese medicine (TCM) enterprises. It specialises in research and development, production and sales of TCM and owns two pharmaceutical production and sale enterprises - Tianjin Tongrentang and Hongrentang which are recognised as two of the fortythree time-honoured pharmaceutical brands granted by the Ministry of Commerce. Tianjin Tongrentang and Hongrentang hold a combined number of 99 valid drug approvals, including a nationalprotected variety, 20 exclusive varieties and 29 drugs that are included in China’s national medical insurance. Tianjin Tongrentang has a well-developed, extensive distribution network throughout China.
*
NOV 2016 OMNI INNOVATION SECURES UK Distribution Deal
Highlights
1) Omni Innovation has entered into a binding exclusive product license term sheet with Healthspan which is the UK’s number one direct supplier of vitamins and supplements
2) The 15-year agreement is to license Omni Innovation’s technology behind its flagship formulation to reduce meal GI by an average of 35%
3) The agreement will provide Healthspan’s customers direct access to this ground breaking technology
*
DEC 2016 Refresh Group Ltd (Refresh) is pleased to announce that it has taken up a $300,000 placement of shares in Eve Investments Ltd (EVE)
2017
*
JAN 2017 Sales Results Exceed Expectations for Faulding® GlucoControlTM
Highlights
1) Release of first Faulding® GlucoControlTM sales following marketing launch in late September 2016
2) 2016 Q4 Sales achieved over 40,000 sachets through pharmacy sales in Australia
3) Faulding® GlucoControlTM is now available in approximately 800 pharmacies across Australia
4) Key Opinion Leaders providing positive feedback on Faulding® GlucoControlTM
*
MAR 2017 OMNI INNOVATION: US Patent Notice of Allowance Received
*
MAY 2017 Eve Invests in Pioneering Cannabis Honey & Tea Tree Oil Co
Highlights
1)EVE enters a binding term sheet to acquire a 50% interest in an established organic essential oils producer from Jenbrook, for total consideration of $1.49m
2) Acquisition of multiple assets across the production and sales value chain for 100% Australian organic essential oils, extracts and distillate waters
3)Doubling of revenue expected from established products and existing US customer base: $1.6m annualised monthly revenue anticipated for June 2017, 100% increase from June 2016
4) Unique and exciting product expansion, with confirmed US customer demand for two new product opportunities:
Medicinal cannabis honey – a premium honey product, produced by bees pollinating on hemp or medicinal cannabis plant nectar
Melaleuca (Meluka) honey – superior antibacterial honey produced by bees pollinating on melaleuca tea trees
5)Strongly positioned to disrupt the large and growing global Manuka honey market, estimated in 2015 to have a global import market of around US$2.1 b1, leveraging its established manufacturing facilities
and US sales channel.
*MAY 2017 Appointment of Leading Medicinal Cannabis Advisor : BuddingTech
BuddingTech is an advisor and accelerator company focused on the Australian medicinal cannabis industry • It will advise on all regulatory requirements for Medic Honey’s planned premium cannabis honey product, produced by bees pollinating on hemp or medicinal cannabis plant nectar • Appointment accelerates Medic Honey’s strategy to disrupt the Manuka honey market worth over $US2.1 billion in global import value and enter the medicinal cannabis market with an innovative new product.
*
MAY 2017 Southern Cross University Collaboration with Medic Honey
*
AUG 2017 OMNI INNOVATION enters
Chinese Distribution Deal
EAGLE HEALTH SELECTED AS OMNI INNOVATION’S CHINESE PARTNER FOR MANUFACTURING, MARKETING AND DISTRIBUTION
* SEP 2017 Omni Innovation Executes Chinese Licence Agreement EVE Investments provides for your information a copy of a release made by Eagle Health Holdings (ASX:EHH) today on completion of the Licence Agreement with EVE’s portfolio company, Omni Innovation.
Omni Innovation is a medical technology company focused on medical nutrition in which EVE has
a ~40% interest
*
OCT 2017 EAGLE HEALTH commences Production of OMNI's Pre-Meal Diabetes Shake
*
NOV 2017 Meluka Health appoints Lreading Bee and Honey Advisor
Appointment of David Rudd
Meluka Health has appointed Dr. David Rudd as a special advisor to the Meluka Health board. Dr Rudd will be providing specialist advice on product development, evaluation and efficacy for a range of Meluka Honey products incorporating;
1) Medicinal/Therapeutic Honey – ingestible therapeutic honey
2) Topical Honey Balm – for burns and wound application
3) Bee Tonic – bee health product
* NOV 2017 Supply Agreement with large producer of Australian Organic Honey.
EVE Investments (ASX:EVE), an ASX-listed technology investment company, is pleased to provide an update on Meluka Health, a Company it is acquiring a 50% interest in. Meluka Health has entered two supply agreements with Bee Services, one of Australia’s largest producer of organic certified honey.
1) The first agreement is an exclusive supply agreement for honey produced from hives located on two organic melaleuca tea tree plantations, Jendale and Robyndale, located in the Bungawalbyn valley basin of NSW. Jendale is an old growth plantation that is wild crafted in its natural state and has been identified as an origin of the species plantation for the melaleuca alternifolia. Robyndale is a farmed organic melaleuca tea tree plantation.
2) The second agreement is for supply of honey that is produced in the region of the Bungawalbyn valley basin. Meluka Health is happy to have secured honey supply from such a capable and well respected producer who has the same organic and ecological ethos for the supply of its unique and high quality honey. Production has already commenced under both agreements.
*
NOV 2017 MEDIC HONEY produces a Hemp Seed Honey
Leveraging the recent changes in Australian legislation that allow Hemp food products to be consumed by humans, Medic Honey has completed formulation and production of Australia’s first 100% organic
Hemp Seed Honey.
The product will be sold under Medic Honey’s ‘Meluka’ brand and will be ready for wholesale distribution by the end of this year with branding to be completed in the next month. Direct consumer distribution will be commenced in quarter one of 2018. Medic Honey will market this product itself into the Australian market. The Hemp Seed Honey will be marketed into the US by distribution company Naturally Australian Products (NAP) to wholesalers and manufacturers. NAP has been appointed Medic Honey’s US distributor.
*
NOV 2017 NSW Grant for Honey Research Successful
Award of TechVouchers Grant Meluka Health is pleased to announce that an application for a NSW TechVoucher grant to support the Bee Health and honey research program has been successful. TechVouchers is a program where SMEs
can be connected with an expert in a relevant field of research and embark on an innovative joint
research project.
Take your time and read through these ANN's to see where EVE has been and is heading for 2018
(20min delay)